Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-117 in Multifocal Motor Neuropathy (ARDA+)
NCT05405361Phase 2Active, not recruiting
- Sponsor
- argenx
- Start
- Jan 2023
- Primary completion
- Sep 2029
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of empasiprubart in multifocal motor neuropathy (MMN), sponsored by argenx. Started Jan 2023; status: active, not recruiting.
02
Drugs
empasiprubart
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on NCT05405361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405361.